PDE4A and bronchopulmonary dysplasia: Our findings indicate both the narrow therapeutic window of PDE4 inhibitors in the developing lung, and the need for further research in the approach to modulate lung inflammation, support developmental processes in the preterm lung, and prevent BPD.